Exposure–Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer by Kelong Han et al.
Research Article
Exposure–Response and Tumor Growth Inhibition Analyses of the Monovalent
Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line
Non-Small Cell Lung Cancer
Kelong Han,1,6 Pascal Chanu,2 Fredrik Jonsson,3 Helen Winter,4 René Bruno,5,6 Jin Jin,4 and Mark Stroh4
Received 3 July 2016; accepted 12 December 2016; published online 27 December 2016
Abstract. The phase III trial comparing onartuzumab + erlotinib vs. erlotinib in the
second- and third-line non-small cell lung cancer (NSCLC) did not meet its primary endpoint
of overall survival (OS). The objective was to assess whether doses higher than the phase III
dose (15 mg/kg) might yield better efﬁcacy without compromising the safety proﬁle. Data
were from 636 patients from the phase II and III NSCLC studies. Tumor growth inhibition
(TGI) models were ﬁt to longitudinal tumor size data to estimate individual TGI metrics
including time to tumor re-growth (TTG). Cox regression models were developed for time-
to-event endpoints (progression-free survival (PFS), OS, and TTG) to investigate relation-
ships with baseline prognostic factors and onartuzumab exposure. Incidence of adverse
events was modeled by logistic regression. In the ﬁnal models, higher onartuzumab exposure
was associated with longer PFS, but not with longer OS. Longer OS was associated with
higher baseline albumin, longer TTG, smaller number of metastatic sites, female gender,
lower ECOG score, and younger age. TTG was the only TGI metric retained in the ﬁnal OS
model. Onartuzumab exposure was not signiﬁcantly associated with TTG after adjusting for
prognostic factors. Higher Cmin was associated with increased incidence of infusion reactions
and peripheral edema. Higher onartuzumab exposure was not signiﬁcantly associated with
improved OS after adjusting for prognostic factors and TTG, and there was a trend of
unknown clinical signiﬁcance toward increased incidence of infusion reactions and peripheral
edema. These results did not support testing higher onartuzumab doses.
KEY WORDS: Cox regression; exposure–response; NSCLC; onartuzumab; survival model; time to
tumor re-growth; tumor growth inhibition.
INTRODUCTION
c-MET is a receptor tyrosine kinase and plays a key role
in a variety of cellular processes including motility, morpho-
genesis, proliferation, and survival and invasion and may also
contribute to angiogenesis (1). Clinically, the c-MET pathway
has been strongly linked to oncogenic potential. First,
activating kinase domain mutations have been described in
a variety of cancers, with particularly high levels observed in
renal papillary carcinoma patients (2,3). Second, high levels
of tumoral expression of c-MET and/or its ligand hepatocyte
growth factor (HGF) have been correlated with worse
prognosis in several tumor types, including non-small cell
lung cancer (NSCLC), breast cancer, ovarian cancer, cervical
cancer, gastric cancer, transitional bladder carcinoma, glio-
blastoma, head and neck cancers, and multiple myeloma (4–
13). Collectively, these provide compelling evidence that
therapeutics abrogating c-MET activation warrant clinical
evaluation.
Onartuzumab (MetMAb) is a recombinant humanized
monoclonal monovalent anti-c-MET antibody that binds the
extracellular domain of c-MET, blocking HGF ligand binding,
and inhibiting subsequent receptor activation. In a random-
ized placebo-controlled phase II study in recurrent NSCLC
(OAM4558g, ClinicalTrials.gov Identiﬁer: NCT00854308),
onartuzumab plus erlotinib signiﬁcantly improved
progression-free survival (PFS) and overall survival (OS) as
compared to erlotinib plus placebo in MET-positive (MET
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immunohistochemistry diagnostic positive) patients (14).
However, in a double-blind randomized placebo-controlled
phase III study in recurrent NSCLC (OAM4971g,
ClinicalTrials.gov Identiﬁer: NCT01456325), onartuzumab
plus erlotinib did not signiﬁcantly improve PFS or OS as
compared to erlotinib plus placebo in MET-positive patients
(15).
The onartuzumab dose used in the phase III study,
15 mg/kg administered once every 3 weeks (Q3W), was
supported by cumulative preclinical and clinical experience.
Simulations based on a population pharmacokinetic (PK)
model derived from phase I study OAM4224g and phase II
study OAM4558g suggested that onartuzumab 15 mg/kg
Q3W would achieve a target tumoristatic trough concentra-
tion of 15 μg/mL, which was derived from xenograft studies
(16). However, OAM4224g showed that onartuzumab was
tolerable up to 30 mg/kg (17), opening up the possibility of
dose intensiﬁcation.
In order to facilitate the interpretation of the phase III
outcomes and assess whether further dose intensiﬁcation
might yield better efﬁcacy without compromising the safety
proﬁle, exposure–response analyses were conducted. How-
ever, exposure–response models may be confounded by
disease severity and prognostic factors that may be observed
(e.g., albumin, ECOG score, number of metastatic sites) or
unobserved (e.g., inﬂammatory status). Confounding is re-
lated to the fact that disease severity and health status may
impact both OS and PK (18,19), especially for monoclonal
antibodies. One way to address the confounding issue is to
incorporate an explanatory variable, such as TGI metrics as
illustrated in the causal pathway in Fig. 1 (18) to make
inferences about OS.
The objectives of these analyses were to (1) assess the
relationship between onartuzumab exposure and efﬁcacy as
well as safety and (2) estimate TGI metrics and assess
onartuzumab exposure–TGI and TGI–efﬁcacy relationships
(18).
METHODS
Patients and Exposure Metrics
Onartuzumab PK, efﬁcacy, and safety data were
obtained from OAM4558g (14) and OAM4971g (15). The
clinically relevant covariates tested included those related to
demographics, laboratory tests, concomitant medications, and
pathophysiological factors (Table I). Onartuzumab serum
concentrations were determined at Genentech Inc. by a
validated sandwich enzyme-linked immunosorbent assay
described previously that was designed to measure free
onartuzumab (16). The lower limit of quantiﬁcation
(LLOQ) was 0.2 μg/mL.
Erlotinib was administered at the approved daily oral
dose of 150 mg. Onartuzumab was administered at 15 mg/kg
via intravenous infusion once every 3 weeks. Per study
protocol, patients in the erlotinib arm were allowed to cross
over to the onartuzumab + erlotinib arm after disease pro-
gression. A population PK model of onartuzumab (two-
compartment model with linear elimination) has been previ-
ously established (16) based on data from phase I and II
studies. The estimates for clearance (CL), central volume of
distribution (V1), and terminal half-life were 0.439 L/day,
2.77 L, and 13.4 days, respectively. Onartuzumab CL
increased with creatinine CL. Onartuzumab V1 increased
with body weight and was higher in males. Onartuzumab
peripheral volume of distribution increased with body weight.
Exposure of onartuzumab or erlotinib was not associated with
MET diagnostic status (degree of tissue MET expression). No
pharmacokinetic drug–drug interaction was observed be-
tween onartuzumab and erlotinib.
Non-linear mixed effects modeling was performed with
NONMEM (version 7.3; ICON Development Solutions,
Ellicott City, Maryland, USA) (20) using the FOCE method
of estimation with interaction, Perl-speaks-NONMEM (ver-
sion 3.5.3; Uppsala University, Uppsala, Sweden) (21), and R
3.0.1 (22). Serum concentration data were ﬁt to the previously
published population PK model (16) to obtain individual
empirical Bayesian estimates of PK parameters (post hoc step
using NONMEM (20)), which were subsequently used to
derive the individual onartuzumab exposure (trough (Cmin)
and peak (Cmax) concentration and area under the concen-
tration time curve (AUC)) during the ﬁrst dosing interval and
at steady state (ﬁfth dosing interval). AUC was calculated
using the trapezoidal method. Patients in the erlotinib single-
agent arm were assumed to have an onartuzumab exposure of
zero. Exposure was tested both as continuous variable and
categorical variable (quartiles and tertiles).
Longitudinal Tumor Size Modeling
Longitudinal tumor size, deﬁned as the sum of the
longest diameters of target lesions according to the RECIST
criterion (23), was analyzed. Patients with at least two tumor
size measurements were deﬁned as evaluable. Two TGI
models (Supplementary Material) previously proposed were
ﬁt to data from evaluable patients using NONMEM: a bi-
exponential model (24) and a simpliﬁed TGI (sTGI) model
(25). Shrinkage in parameter estimates was estimated (26).
The ﬁts of models were compared using the log-likelihood
ratio test as well as standard goodness of ﬁt plots. These
models were not subjected to any simulation-based assess-
ment since they were not meant to be used for simulation but
only to estimate individual TGI metrics to be tested in the
survival model. Three individual TGI metrics were calculated
using individual post hoc TGI parameter estimates: the
growth rate constant (KG) (24), the TTG (25), and tumor
size ratio to baseline at week 8 (25).
Fig. 1. Causal pathway to the elicitation of treatment effect. TGI
tumor growth inhibition. TGI metrics includes the growth rate
constant (KG) (24), the time to tumor re-growth (TTG) (25), and
tumor size ratio to baseline (25)
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Exposure–Response Analysis of Efficacy Endpoints
Time-to-event variables (PFS, OS, and TTG) were ex-
plored and compared between patient subgroups with different
onartuzumab exposure using Kaplan–Meier analysis and log-
rank test. Multivariate models were developed using Cox
regression analysis to associate time-to-event variables with
onartuzumab exposure, clinically relevant covariates, and TGI
metrics (when applicable). A Bfull^model was built by including
all signiﬁcant covariates from the Cox univariate analysis
(p < 0.05 as per the log-likelihood ratio test where the difference
in −2*log-likelihood (score) between the alternative models
follows a χ2 distribution). If several exposure or TGI metrics
were signiﬁcant from the univariate analysis, only the most
signiﬁcant one was included in the full model. Then, a backward
stepwise elimination was carried out. At each elimination step,
the relative inﬂuence of each remaining covariate on the model
was re-evaluated one by one by deleting it from the reduced
model using a cutoff of p < 0.01. The model was built only based
on the patient subset with complete information without
imputation. The PFS model was developed without inclusion
of TGI metrics as covariates in MET-positive patients because
tumor response was already considered and included in the
overall clinical assessment of PFS.
Exposure–Response Analysis of Safety Endpoints
The safety endpoints (adverse events) were character-
ized by frequency (yes/no). The proportions of frequency and
95% conﬁdence intervals were computed for intervals of
onartuzumab exposure with an equivalent number of individ-
uals (e.g., quartiles or tertiles). The correlation between each
safety endpoint and onartuzumab exposure subgroups was
tested using logistic regression and the Wald test. Multivariate
logistic regression models were developed only for the safety
endpoints that showed a statistically signiﬁcant (p < 0.05)
correlation with any onartuzumab exposure metrics. All
candidate covariates and exposure metrics were tested in a
univariate and multivariate manner with the signiﬁcance level
of p < 0.05. The model was built only based on the patient
subset with complete information without imputation.
RESULTS
Patients and Exposure Metrics
Data from a total of 636 patients were collected. Baseline
patient characteristics evaluated as covariates are summarized
in Table I. Both MET-positive and MET-negative patients
were enrolled in OAM4558g, while only MET-positive
patients were enrolled in OAM4971g. In OAM4558g, 27
patients (13 MET-positive, 12 MET-negative, and 2 unknown
MET status) in the placebo arm received onartuzumab at
some point (crossover patients) and thus were excluded from
the analysis. Exposure data were unavailable in three patients
who received onartuzumab, leaving 606 patients included in
the analysis (550 MET-positive). PK parameter estimates
Table I. Patient Characteristics by Treatment
Onartuzumab arm Placebo arm
Total number of patients 319 317
Study (OAM4558g:OAM4971g)a 69:250 68:249
Age (year) 63 [24∼83] 63 [27∼84]
Gender (female:male)a 140:179 136:181
Body weight (kg) 69.1 [41.9∼119.8] 70.1 [32.8∼141]
Asian patientsb 11.6% 12.0%
ECOG score (0:1:2)a 115:196:8 99:214:3
Stage (IIIB:IV)a 82:237 78:239
Non-squamous:squamousa 283:36 281:36
Albumin (g/L) 39 [25∼49] 39 [24∼49]
Total protein (g/L) 70 [0.072∼96] 69 [6.9∼94]
Baseline tumor burden (mm) 47.5 [1∼245] 48 [1∼324]
Number of metastatic sites 3 [1∼8] 2.5 [1∼9]
More than one metastatic siteb 75.5% 81%
Liver metastasis presentb 20.7% 20.2%
Smoking history (current:previous:never)a 50:209:59 57:208:50
EGFR mutation (yes:no:missing)a 43:232:44 41:237:39
KRAS mutation (yes:no:missing)a 36:80:203 27:101:199
MET mutation (yes:no:missing)a 270:31:18 271:31:15
Time since diagnosis (months) 11.8 [0.46∼90.7] 12.4 [1.87∼97.3]
Estimate of TTG (weeks) 1.445 [−44.62∼68.50] 1.357 [−36.68∼70.49]
Tumor size ratio to baseline at week 8 1.010 [0.199∼3.458] 1.010 [0.144∼1.879]
Estimate of KG (per week) 0.0083 [0.0043∼0.1558] 0.0083 [0.0028∼0.0803]
Patients in the onartuzumab arm receive both erlotinib and onartuzumab. Patients in the placebo arm received erlotinib alone. The numbers
displayed represent the median (range) except for the number of patients is displayed (superscript letter a) and the percentage of patients is
displayed (superscript letter b)
ECOG score Eastern Cooperative Oncology Group performance score, EGFR epidermal growth factor receptor, KG growth rate constant,
KRAS Kirsten rat sarcoma viral oncogene homolog, MET hepatocyte growth factor receptor, TTG time to tumor re-growth
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based on the PK data from OAM4558g and OAM4971g were
consistent with those previously reported (16).
Longitudinal Tumor Size Modeling
Two TGI models were ﬁt to the longitudinal tumor size
data. A total of 584 patients were evaluable for TGI
modeling. Parameter estimates and goodness-of-ﬁt plots for
these two TGI models were summarized in Supplementary
Tables 1 and 2 and Supplementary Figures 1 and 2. Both
models provided adequate ﬁt to the data with a slightly better
ﬁt by the bi-exponential model. The KG, TTG, and tumor
size ratio to baseline at week 8 were derived.
Exposure–Response Analysis for Survival
The highest quartile of onartuzumab steady-state Cmin
(Cmin,ss) was associated with a longer PFS (median
4.37 months) than the other three quartiles (median
2.50 months) and the placebo arm (median 2.50 months)
(Fig. 2) (Supplementary Tables 3 and 4). Univariate Cox
regression analysis for OS (Table II) showed a strong
association between OS and TTG (p < 0.0001). The associa-
tion between OS and tumor size ratio or log (KG) was
statistically signiﬁcant (p < 0.0001), but not as strong as TTG.
The ﬁnal OS model (Table III) was obtained by multivariate
backward stepwise elimination. In this model, none of the
exposure metrics was signiﬁcant (p > 0.05) whether they were
considered a continuous variable or a categorical variable
with the upper quartile as threshold.
Correlation Between Time to Tumor Re-growth and
Onartuzumab Exposure
As illustrated in Fig. 1, one possible reason why
onartuzumab exposure was eliminated from the ﬁnal OS
model could be due to the potential association between
longer TTG and higher onartuzumab exposure. Therefore,
this was subsequently examined by univariate and multivar-
iate Cox regression analysis linking TTG with baseline
prognostic factors and onartuzumab exposure.
The univariate Cox regression analysis for TTG is
summarized in Supplementary Table 5. EGFR mutation
status and baseline albumin were selected to remain in the
ﬁnal TTG model as independent predictors for TTG (Ta-
ble III). In the ﬁnal TTG model, the presence of EGFR
mutation and higher albumin was associated with longer
TTG. None of the onartuzumab exposure metrics was
signiﬁcant in the ﬁnal TTG model. There was no interaction
between onartuzumab Cmin,ss and MET diagnostic status.
Exposure–Response of Safety Endpoints
Seven adverse events were evaluated: infusion reactions,
allergic reactions, venous thromboembolism, arterial throm-
boembolism, interstitial lung disease, gastrointestinal perfo-
rations, and peripheral edema. Peripheral edema data were
unavailable in OAM4558g. Exploratory logistic regression
showed that only infusion reactions and peripheral edema
were statistically signiﬁcantly associated with onartuzumab
exposure (Fig. 3). The ﬁnal logistic regression (Table III) was
obtained by multivariate logistic regression. Among all
Fig. 2. Kaplan–Meier plot comparing progression-free survival by
onartuzumab exposure. Cmin,ss onartuzumab steady-state trough
serum concentration with an upper quartile threshold of 79 μg/mL
Table II. Univariate Cox Regression Analysis for Overall Survival
Covariate Score p value Number Sign
Albumin (g/L) 26.8 <0.0001 506 –
Number of metastatic sites 21.4 <0.0001 587 +
Estimate of TTG (weeks) 20.5 <0.0001 582 –
Baseline tumor burden (mm) 16.4 <0.0001 582 +
More than one metastatic site 14.9 <0.0001 587 +
ECOG score >0 14 <0.0001 606 +
TR to baseline at week 8 12.4 <0.0001 582 +
EGFR mutation positive 11.4 <0.0001 606 –
log (KG) 9.9 <0.0001 582 +
Gender =male 7.5 0.0001 606 +
Current smoker 7.2 0.0001 606 +
Cmin,ss >77 μg/mL 6.2 0.0005 606 –
Liver metastasis present 4.9 0.0017 606 +
Time since diagnosis (month) 4.6 0.0024 584 –
Asian ethnicity 3.2 0.012 606 –
Age (year) 2.2 0.0352 606 –
Onartuzumab treatment 0.5 0.3093 606 +
OAM4558g study 0.1 0.6789 606 –
MET mutation positive 0.1 0.7426 600 –
Covariates are ordered by the level of signiﬁcance (score). Covariates
tested included all baseline covariates, onartuzumab exposure, and
TGI (tumor growth inhibition) metrics. p value is calculated using the
likelihood ratio test. Score means the difference in −2*log-likelihood
between the alternative models following a χ2 distribution. Sign is the
death hazard increases (+) or decreases (−) with the increased value
of the covariate with a positive sign indicating bad prognosis
Abbreviations: Cmin,ss steady-state trough onartuzumab serum
concentration with an upper quartile threshold of 77 μg/mL, ECOG
score Eastern Cooperative Oncology Group performance score,
EGFR epidermal growth factor receptor, KG growth rate constant,
N number of patients with available information of the speciﬁc
covariate, TR tumor size ratio to baseline, TTG time to tumor re-
growth
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baseline prognostic factors and onartuzumab exposure met-
rics tested, only onartuzumab Cmin,ss in the highest quartile
was associated with increased incidence of infusion reactions,
and only increased onartuzumab Cmin,ss was associated with
increased incidence of peripheral edema.
DISCUSSION
The phase III trial OAM4971g comparing onartuzumab
plus erlotinib vs. erlotinib in MET-positive patients with the
second- and third-line NSCLC did not meet the primary
endpoint of OS. This analysis was performed to assess
whether higher onartuzumab doses might yield better efﬁcacy
without compromising the safety proﬁle. Our analysis dem-
onstrated that higher onartuzumab PK exposure was not
associated with improved OS after accounting for baseline
prognostic factors and TGI metrics, but there was a trend of
unknown clinical signiﬁcance toward increased incidence of
infusion reactions and peripheral edema. These results did
not support testing of a higher onartuzumab dose in this
population.
Exploratory analysis suggested that patients with the
onartuzumab steady-state trough concentration (Cmin,ss)
above the highest quartile tended to have a longer OS than
patients with Cmin,ss in the lowest three quartiles, who had
similar or even slightly lower OS as compared to patients
receiving erlotinib alone. In the ﬁnal multivariate model after
adjusting for baseline prognostic factors and TGI metrics,
higher Cmin,ss was no longer signiﬁcantly associated with
longer OS.
Exposure–response models may be confounded by
observed and unobserved prognostic and disease risk factors
(18,19). Prognostic factors may impact both OS and PK
exposure (Fig. 1), especially for antibody drugs. Patients with
the characteristics related to poor prognosis (e.g., low
albumin and high ECOG score) have demonstrated faster
clearance and thus lower exposure for large molecule drugs
(27). This may be adjusted for by using multivariate models
incorporating baseline prognostic factors, such as the Cox
regression employed in this analysis. The resulting multivar-
iate models may be used to simulate the expected response
under unstudied doses (28). However, such simulations may
lead to biased inferences if the confounding is not fully
Table III. Parameter Estimates of Final Models for Efﬁcacy and
Safety Endpoints
Parameter Estimate RSE z p value
Final OS model a
Baseline albumin (g/L) −0.09545 15.1 −6.61 <0.0001
Estimate of TTG (weeks) −0.02413 17.4 −5.73 <0.0001
Number of metastatic sites 0.22365 19.5 5.13 <0.0001
Gender =male 0.5510 25.1 3.98 <0.0001
ECOG score >0 0.4450 33.9 2.95 0.0032
Age (year) −0.01891 35.2 −2.84 0.0045
Final TTG model b
EGFR mutation positive −0.802 16.9 −5.91 <0.0001
Baseline albumin (g/L) −0.0287 35.9 −2.78 0.0054
Infusion reactionsc
(Intercept) −1.78 7.30 −13.7 <0.0001
Cmin,ss >79 μg/mL 0.915 31.8 3.14 0.0017
Peripheral Edemac
(Intercept) −2.17 8.39 −11.9 <0.0001
Cmin,ss (μg/mL) 0.0166 18.6 5.37 <0.0001
p value: Wald test (χ2 ). z: Wald statistic
Abbreviations: Cmin,ss steady-state trough onartuzumab serum
concentration with an upper quartile threshold of 79 μg/ml, ECOG
score Eastern Cooperative Oncology Group performance score,
EGFR epidermal growth factor receptor, OS overall survival. RSE
relative standard error (%) indicating the precision of parameter
estimation, TTG time to tumor re-growth
aDeveloped using multivariate Cox regression models to associate
OS with all baseline covariates, onartuzumab exposure, and tumor
growth inhibition metrics
bDeveloped using multivariate Cox regression models to associate
TTG with all baseline covariates and onartuzumab exposure
cDeveloped using multivariate logistic regression models to associate
the incidence of adverse events with all baseline covariates and
onartuzumab exposure
Fig. 3. Exposure–safety relationship for infusion reactions and
peripheral edema. The model-predicted incidence with 95% predic-
tion interval was generated by the ﬁnal logistic regression model.
Onartuzumab concentration was assumed to be zero in the placebo
arm. Observed incidence was calculated with error bar in the placebo
arm and in each concentration quartile in the treatment arm. The
number displayed above each observed incidence was the corre-
sponding number of patients and calculated incidence
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adjusted for. One way to address the confounding issue is to
incorporate an explanatory variable, such as TGI metrics, as
illustrated in the causal pathway (18) in Fig. 1. A good
example has been established using data for trastuzumab in
HER2-positive gastric cancer (29). The multivariate OS
model accounts for both baseline prognostic factors and
treatment effect on TGI. Assuming that the drug effect is
mediated via TGI, the direct exposure−OS link should be
removed when TGI enters the OS model, which has been the
case in this analysis. If the exposure–OS link is valid, valid
inferences can be made assuming exposure impacts TGI and
TGI impacts OS. However, there was no exposure–TGI link
in this analysis, demonstrating that a valid exposure–OS link
does not exist.
In this analysis, TGI metrics were estimated based on
longitudinal tumor size data (18). The estimate of time to
tumor re-growth (TTG) was a strong predictor for OS as
observed in previous studies using similar methodologies
(18). TTG remained a strong predictor of OS after adjust-
ment for baseline prognostic factors. In the univariate
analysis for TTG, patients with the onartuzumab Cmin,ss
above the highest quartile tended to have longer TTG.
However, the main covariate effects were EGFR mutation
status and baseline albumin with EGFR-mutated patients
with higher albumin having a trend to have longer TTG. It is
well known that EGFR-mutated patients respond better to
erlotinib treatment than other patients, and patients with
higher albumin are healthier and usually show better clinical
outcomes than patients with lower albumin. Onartuzumab
exposure was no longer signiﬁcant after adjusting for EGFR
mutation status and albumin, suggesting that onartuzumab
treatment had no discernable effect on TGI and that the
exposure–OS relationship observed in the exploratory anal-
ysis was mainly due to disease prognostic.
The exposure–response analysis was performed for all
seven selected adverse events without distinguishing
onartuzumab-related or erlotinib-related adverse events.
Statistically signiﬁcant relations between onartuzumab
Cmin,ss and infusion reactions and peripheral edema were
observed. In the multivariate analyses, no baseline prognostic
factors entered the model and onartuzumab exposure was the
only predictor. For infusion reactions, the incidence appeared
to be increased in patients with the onartuzumab Cmin,ss
above the highest quartile. In addition, the incidence was
notably higher in OAM4558g than in OAM4971g, likely due
to the higher onartuzumab concentrations in OAM4558g.
Onartuzumab Cmin,ss in 34% of patients in OAM4558g but
only 24% in OAM4971g were above the highest quartile
threshold of 79 μg/mL. However, this result should be
interpreted with caution because an infusion reaction might
be caused by infusion that lasted longer than was pre-
speciﬁed in the protocol, especially when a higher dose was
given. Unfortunately, this could not be further evaluated due
to the lack of information on the exact time when the infusion
reaction occurred. In contrast, the incidence of peripheral
edema appeared to be associated with onartuzumab exposure
that was evaluated as either a continuous or categorical
variable, and all onartuzumab exposure metrics were statis-
tically signiﬁcant. The clinical signiﬁcance of the exposure–
response relationships for infusion reactions and peripheral
edema was unclear.
There are several limitations in this analysis. First, only
one dose level (15 mg/kg) was evaluated in the phase II and
phase III studies, which may limit the range of exposure.
However, onartuzumab Cmin,ss ranged from 5.2 to 185 μg/
mL in the pooled data, with a coefﬁcient of variation (CV) of
46%. This may provide an adequately wide range of exposure
to be tested in the model. Second, there was some shrinkage
in parameter and individual estimates of the TGI metrics
(Supplementary Tables 1 and 2). Shrinkage might decrease
the predictive power of these metrics. However, all the
metrics were still strong predictors of OS indicating that the
shrinkage was not a major problem.
In conclusion, in patients with second- and third-line
NSCLC, higher onartuzumab PK exposure was not associated
with improved OS after accounting for baseline prognostic
factors and TGI metrics, but there was a trend of unknown
clinical signiﬁcance toward increased incidence of infusion
reactions and peripheral edema. Collectively, these results did
not suggest that dose intensiﬁcation would improve clinical
outcomes and thus did not support further clinical investiga-
tion of a higher onartuzumab dose in this population.
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